Altimmune, Inc.(ALT)
Biotechnology
Oncology Biotech
| Filing Date | Insider | Type | 10b5-1 | Net Shares | Ownership change | Avg. Price | Value | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-04-06 | GILL JOHN Director | Purchase | +9,200 | +73.60%21,700 | $3.41 | $31,350 | View SEC filing | |
| 2026-04-01 | Durso Jerome Benedict President and CEO | Purchase | +15,000 | +46.15%47,500 | $3.14 | $47,100 | View SEC filing | |
| 2026-04-01 | WEAVER GREGORY L Chief Financial Officer | Purchase | +10,000 | +35.62%38,078 | $3.15 | $31,499 | View SEC filing | |
| 2026-03-09 | Durso Jerome Benedict President and CEO | Purchase | +20,000 | +160.00%32,500 | $3.54 | $70,790 | View SEC filing | |
| 2026-03-09 | WEAVER GREGORY L Chief Financial Officer | Purchase | +5,000 | +21.67%28,078 | $3.54 | $17,700 | View SEC filing | |
| 2026-01-09 | Pisano Wayne Director | Purchase | +5,000 | +58.84%13,498 | $4.08 | $20,410 | View SEC filing | |
| 2026-01-05 | Sohn Catherine A. Director | Purchase | +500 | +50.00%1,500 | $4.24 | $2,118 | View SEC filing | |
| 2025-12-29 | Jorkasky Diane Director | Purchase | +527 | +100.00%527 | $3.80 | $2,003 | View SEC filing | |
| 2025-12-23 | GILL JOHN Director | Purchase | +12,500 | +100.00%12,500 | $4.10 | $51,250 | View SEC filing | |
| 2025-12-22 | Durso Jerome Benedict Director | Purchase | +12,500 | +100.00%12,500 | $4.13 | $51,569 | View SEC filing | |
| 2025-03-18 | Sohn Catherine A. Director | Purchase | +1,000 | +100.00%1,000 | $5.78 | $5,785 | View SEC filing | |
| 2025-03-14 | WEAVER GREGORY L Chief Financial Officer | Purchase | +10,000 | +100.00%10,000 | $5.20 | $51,996 | View SEC filing | |
| 2024-08-20 | Drutz David Director | Sale | -16,011 | +11.53%55,524 | $6.90 | $110,547 | View SEC filing | |
| 2023-08-15 | Drutz David Director | Purchase | +300 | +1.02%29,785 | $2.88 | $863 | View SEC filing | |
| 2023-07-06 | GILL JOHN Director | Sale | -2,714 | -49.48%2,771 | $15.00 | $40,710 | View SEC filing | |
| 2023-03-27 | Drutz David Director | Purchase | +9,000 | +43.94%29,484 | $4.27 | $38,430 | View SEC filing | |
| 2023-03-24 | Eisenstadt Richard I Chief Financial Officer | Purchase | +10,000 | +83.26%22,010 | $4.31 | $43,140 | View SEC filing | |
| 2023-03-23 | Harris Matthew Scott Chief Medical Officer | Purchase | +10,000 | +42.90%33,311 | $4.22 | $42,200 | View SEC filing | |
| 2022-12-22 | Pisano Wayne Director | Sale | -20,000 | -70.18%8,498 | $15.01 | $300,268 | View SEC filing | |
| 2022-09-01 | Garg Vipin K President and CEO | Sale | -20,000 | -7.79%236,797 | $20.02 | $400,322 | View SEC filing | |
| 2022-08-12 | Garg Vipin K President and CEO | Sale | -15,000 | -5.46%259,804 | $15.06 | $225,890 | View SEC filing | |
| 2022-07-05 | Roberts M Scot Chief Scientific Officer | Sale | -37,164 | -81.41%8,305 | $12.00 | $445,968 | View SEC filing | |
| 2022-06-30 | Roberts M Scot Chief Scientific Officer | Sale | -5,462 | -23.58%17,700 | $12.00 | $65,546 | View SEC filing | |
| 2022-06-28 | Roberts M Scot Chief Scientific Officer | Sale | -37,352 | -67.85%17,700 | $12.00 | $448,254 | View SEC filing | |
| 2022-06-28 | Jorkasky Diane Director | Sale | -17,610 | -100.00%0 | $11.75 | $206,944 | View SEC filing |
1-25 of 156